Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monopar Therapeutics Inc. - Common Stock
(NQ:
MNPR
)
112.55
+5.12 (+4.77%)
Streaming Delayed Price
Updated: 11:09 AM EDT, Jul 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monopar Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 21, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 20, 2024
Via
Benzinga
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 20, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 05, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
December 03, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
3 Momentum Stocks Soaring Into 2025 and Beyond
December 03, 2024
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
Via
MarketBeat
Topics
Stocks
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 08, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
October 28, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 28, 2024
Via
Benzinga
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
October 28, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 28, 2024
Via
Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
October 28, 2024
Via
Benzinga
MarketBeat Week in Review – 10/21- 10/25
October 26, 2024
Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Stocks
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 25, 2024
Via
Benzinga
What's Going On With Monopar Therapeutics Shares Friday?
↗
October 25, 2024
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease.
Via
Benzinga
Monopar Therapeutics Skyrockets 400% on Licensing Deal
October 25, 2024
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.
Via
MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 25, 2024
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
October 25, 2024
Via
Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
↗
October 24, 2024
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.
Via
Benzinga
Topics
Stocks
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
↗
October 24, 2024
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
Via
Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 24, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 22, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 15, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 07, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 01, 2024
Via
Benzinga
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
↗
September 12, 2024
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
Via
Benzinga
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
August 27, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
